

CONTENTS

	Page
Acknowledgement	iii
Abstract in English	iv
Abstract in Thai	vi
List of Tables	xiii
List of Figures	xiv
List of Abbreviations and Symbols	xvi
Statement of Originality in English	xvii
Statement of Originality in Thai	xviii
Chapter I Introduction	1
1.1 Principle and rationale	1
1.2 Lung cancer	2
1.2.1 Types of lung cancer	3
1.2.1.1 Non small cell lung cancer (NSCLC)	3
1.2.1.2 Small cell lung cancer (SCLC)	4
1.3 Lung cancer staging	5
1.4 GM2 activator protein (GM2AP)	6
1.4.1 Biosynthesis of GM2 activator protein	6
1.4.2 Biological role of GM2 activator protein	7
1.4.3 GM2 activator protein and diseases	8
1.5 Proteomics	9
1.5.1 Two-dimensional electrophoresis (2-DE)	11
1.5.2 Mass spectrometry (MS)	12
1.5.2.1 Electrospray ionization mass spectrometry (ESI/MS)	12

CONTENTS (CONTINUED)

	Page
1.5.2.2 Matrix-assisted laser desorption/ionization-time of flight mass spectrometry (MALDI-TOF MS)	13
1.6 Post translational modification	14
1.7 Purpose of the current study	16
Chapter II Materials and Methods	17
2.1 Chemicals and Materials	17
2.2 Methods	17
2.2.1 Sample preparation	17
2.2.1.1 Sample information	17
2.2.1.2 Sample collection	18
2.2.1.3 Protein assay	19
2.2.2 SDS-polyacrylamide gel electrophoresis (SDS-PAGE)	19
2.2.3 Two-dimensional electrophoresis (2-DE)	19
2.2.3.1 IEF/ the first dimension	20
2.2.3.2 PAGE/ the second dimension	20
2.2.4 Protein visualization	20
2.2.4.1 Coomassie Brilliant Blue staining	20
2.2.4.2 SYPRO® Ruby staining	21
2.2.5 Enzyme-linked immunosorbent assay (ELISA)	21
2.2.6 Lectin staining	21
2.2.7 Western blot analysis	22
2.2.8 Immunohistochemical staining (IHC)	22
2.2.9 Protein identification and data annotation	23
2.2.9.1 In-gel enzymatic digestion	23
2.2.9.2 Peptide clean-up using C18 ZipTip®	23
2.2.9.3 Electro-elution for intact protein mass	24

CONTENTS (CONTINUED)

	Page
2.2.9.4 MALDI-TOF mass analysis	24
2.2.9.5 NanoLC-MS/MS analysis	24
2.2.9.6 Data annotation	25
2.2.10 Statistical analyses	25
Chapter III Results	27
3.1 Determination of urinary protein by 2-DE analysis	27
3.1.1 The expression profiles of pooled urinary proteins	27
3.1.2 The expression profiles of individuals urinary proteins	28
3.1.3 Identification of GM2AP spots from 2-DE gel	30
3.2 Identification of GM2AP as a biomarker for lung cancer	31
3.2.1 Confirm of GM2AP spot on 2-DE gels	31
3.2.2 Investigation of kidney function by Western blot analysis	32
3.2.2.1 Patients with anticancer treatments	32
3.2.2.1.1 Urine samples	32
3.2.3 Validation of GM2AP level by Western blot analysis	33
3.2.3.1 Patients with anticancer treatments	33
3.2.3.1.1 Urine samples	33
3.2.3.2 Patients without anticancer treatments	34
3.2.3.2.1 Urine samples	34
3.2.3.2.2 Serum samples	35
3.2.4 Quantification of the GM2AP level by ELISA	36
3.2.4.1 Patients with anticancer treatments in Thailand	36
3.2.4.1.1 Urine samples	36
3.2.4.2 Patients without anticancer treatments in Taiwan	39
3.2.4.2.1 Urine and serum samples	39

CONTENTS (CONTINUED)

	Page
3.2.4.3 Patients with other types of cancer without anticancer treatments in Taiwan	41
3.2.4.3.1 Serum samples	41
3.2.5 The expression of GM2AP in urine and serum of lung cancer and clinicopathological features	43
3.2.6 The expression of GM2AP level in NSCLC tissues	45
3.2.7 The expression of GM2AP in NSCLC tissues and clinicopathological features	46
3.2.8 The expression of GM2AP in NSCLC tissues and survival	47
3.3 Detection of intact protein mass of GM2AP in lung cancer	49
3.4 Determination the glycan structure of GM2AP in lung cancer	50
Chapter IV Discussions and Conclusions	52
4.1 Discussions	52
4.1.1 Elevation of GM2AP level in lung cancer patients	52
4.1.2 Identification GM2AP as biomarker for lung cancer	54
4.1.3 N-linked glycan structure of GM2AP in lung cancer	57
4.2 Practical application	60
4.3 Conclusions	61
References	62
Appendices	72
Appendix A	73
Appendix B	76
Appendix C	78
Appendix D	82
Appendix E	88

CONTENTS (CONTINUED)

	Page
Curriculum vitae	143



ลิขสิทธิ์มหาวิทยาลัยเชียงใหม่
Copyright© by Chiang Mai University
All rights reserved

LIST OF TABLES

	Page
Table 1.1 Staging classifications for lung cancer	5
Table 1.2 Analytical tools in proteomics	10
Table 1.3 The potential role and effect of the glycocomponent of glycoproteins	15
Table 3.1 Quantification of the GM2AP level in lung cancer patient urine samples	38
Table 3.2 The expression level of GM2AP in serum from healthy controls and other types of cancers	41
Table 3.3 Clinicopathological features and distribution in urine and serum levels of GM2AP	44
Table 3.4 Relationship between the GM2AP expression and clinicopathologic features in NSCLS lung tissues	46
Table 3.5 Multivariate analysis of the GM2AP expression in lung cancer patients	48

ลิขสิทธิ์มหาวิทยาลัยเชียงใหม่
Copyright© by Chiang Mai University
All rights reserved

LIST OF FIGURES

	Page
Figure 1.1 Statistics of the ten types of leading cancer in new cases and deaths in United States estimated in 2013	2
Figure 1.2 Schematic representation of the GM2AP structure	6
Figure 1.3 GM2AP stimulated hydrolysis of ganglioside GM2 by β -hexosaminidase A	7
Figure 1.4 Degradation of selected sphingolipids in the lysosomes of the cells	8
Figure 1.5 Two critical steps of two-dimensional electrophoresis (2-DE)	11
Figure 1.6 Mechanism of electrospray ionization	12
Figure 1.7 The schematic representation of a MALDI-TOF/MS	13
Figure 1.8 Cellular post-translational modifications	10
Figure 2.1 Flow chat of proteomic analysis and clinical diagnosis for identify biomarker for lung cancer	26
Figure 3.1 2-DE images of pooled urinary proteins	27
Figure 3.2 2-DE images of individual urinary proteins	28
Figure 3.3 Mascot searches of GM2AP spot from Swiss-Prot database	30
Figure 3.4 Detection of GM2AP on 2-DE gel using antibodies against GM2AP	31
Figure 3.5 Validation of GM2AP level in urine samples of patients with anticancer treatments	32
Figure 3.6 Validation of GM2AP level in urine samples of patients with anticancer treatments	33
Figure 3.7 Validation of GM2AP level in urine samples of patients without anticancer treatments	34
Figure 3.8 Validation of GM2AP level in serum samples of patients without anticancer treatments	35

LIST OF FIGURES (CONTINUED)

	Page
Figure 3.9 ROC curves for expression level of GM2AP in urine samples from patients with anticancer treatments	36
Figure 3.10 Dot histogram pair for expression level of GM2AP in urine samples from patients with anticancer treatments	37
Figure 3.11 ROC curves for expression level of GM2AP in urine and serum samples from patients with anticancer treatments	39
Figure 3.12 Dot histogram pair for expression level of GM2AP in urine and serum samples from patients with anticancer treatments	40
Figure 3.13 A dot histogram plot of other types of cancer	42
Figure 3.14 Immunohistochemical staining of GM2AP in NSCLC	45
Figure 3.15 Kaplan-Meier analyses for GM2AP expression in NSCLC	47
Figure 3.16 MALDI-TOF mass spectra of GM2AP	49
Figure 3.17 Detection of fucosylation on the GM2AP using AAL lectin staining	50
Figure 3.18 Mass spectra of the glycopeptides of urinary GM2AP in lung cancer patients	51

ลิขสิทธิ์มหาวิทยาลัยเชียงใหม่
Copyright© by Chiang Mai University
All rights reserved


LIST OF ABBREVIATIONS AND SYMBOLS

BSA	Bovine serum albumin
DTT	Dithiothreitol
GM2AP	GM2 activator protein
IAA	Iodoacetamide
g	Gram
h	Hour
mg	Milligram
mL	Millilitre
min	Minute
mM	Millimolar
MS	Mass spectrometry
MW	Molecular weight
ng	Nanogram
nM	Nanomolar
PBS	Phosphate buffered saline
rpm	Round per minute
TOF	Time-of-flight
μ	Micro
μ g	Microgram
μ L	Microlitre
α	Alpha
β	Beta
$^{\circ}$ C	Degree Celcius
%	Percentage
v/v	Volume per volume
w/v	Weight per volume

ลิขสิทธิ์มหาวิทยาลัยเชียงใหม่
Copyright© by Chiang Mai University
All rights reserved

STATEMENT OF ORIGINALITY

1. Up-regulation of urinary GM2AP level of lung cancer patients can be considered as novel parameter for clinical development of lung cancer biomarker.
2. The correlation of GM2AP level in urine, serum and tissue specimens could serve as potential diagnostic and prognostic biomarker of lung cancer, especially in early pathologic stages.



ลิขสิทธิ์มหาวิทยาลัยเชียงใหม่
Copyright© by Chiang Mai University
All rights reserved

ข้อความแห่งการริเริ่ม

1. การเพิ่มขึ้นของระดับ GM2AP ในปัสสาวะของผู้ป่วยมะเร็งปอดถือว่าเป็นพารามิเตอร์ใหม่สำหรับการพัฒนาทางคลินิกเพื่อเป็นตัวบ่งชี้ทางชีวภาพของโรคมะเร็งปอด
2. ความสัมพันธ์ของระดับ GM2AP ในปัสสาวะ ซีรัม และตัวอย่างเนื้อเยื่อสามารถทำหน้าที่เป็นตัวบ่งชี้ทางชีวภาพที่มีศักยภาพในการวินิจฉัยและการพยากรณ์ของโรคมะเร็งปอดโดยเฉพาะอย่างยิ่งในระยะต้นของพยาธิวิทยา



ลิขสิทธิ์มหาวิทยาลัยเชียงใหม่
Copyright© by Chiang Mai University
All rights reserved